Member Info for TorquayFan

Thanks it is so good to see you posting again and your 12.13 yesterday now has 56 recs !

Kashdog I really couldn't disagree more with your comments. OF COURSE there has to be a plan at the moment based on what is available at the moment - but why do you surmise the existing plan will not change when something superior comes along ?

With respect you also miss the main point about 'Covidity' - it's hoped and maybe expected that it will provide immunity with more longevity and be well armed in advance, to tackle new variants that we have not seen yet.

Furthermore, 'Covidity' is NOT just a top up vaccine but hopefully a prime vaccine that can bring immunity to the many billions of people around the World who remain unvaccinated.

GLA

Crumbs / Krafty. What I suggested holds together in a spirit of 'spread the word where the interest shows'. Actually I agree with your distaste for the action I didn't suggest. Never mind. Come on Scancell . . . ! ( and England !).

Crumbs IMO there's something in MaxP's idea and it might be worthwhile for someone to get a comment into the 'Straits Times' - Inan's efforts with the DT have borne fruit it seems.

And something added to the CEPI tweet would be possible and not unhelpful to others watching CEPI threads ?

Cleaner Mon 10.02 "In the DT yesterday : "The University of Oxford yesterday injected its new variant vaccine into people for the first time. Academics who created the original jab have updated their blueprint to target the variant first identified in South Africa, also known as B.1.351 or Beta. This Variant of Concern emerged last year and is still in the UK at low levels. It is also less susceptible to the vaccines than other strains, scientists believe. It became the prime candidate for the first “variant vaccine” and the AstraZeneca/Oxford team are now trialling the booster jab — called AZD2816 — in 2,250 volunteers from the UK, Poland, Brazil and South Africa"

It's the original AZ vaccine retuned for 'Beta' . . . .

A. No Cleaner I don't think so. Not at all. BTW this was discussed yesterday starting 10.02

It helps to clarify I think that whilst 'Covidity' might prove to be excellent as a booster embracing variants it can stand alone as a Covid vaccine - in fact I think that's the mode of the trial soon beginning in RSA.

Ruck I thought the 'delivery' work was being done at the Notts Uni's with Scancell so the Prof. might not know but as for this, "Why on earth would he want to mention Scancell?" - it may be naive of me but, if he did know, he's a senior figure and one might hope he might mention that some progress has been made on that front. You know - to give an accurate overview . . .

Chester I don't agree - Scancell have obviously made the 2 delivery methods functional and they are included in the trial submission. I think that's positive data and very much of interest in any well founded comment on 'top-up- vaccines.

AIMHO and GN

Yes Ruck of course that's probable. But it seems strange not to mention Scancell's progress with delivery methods ?

In the DT yesterday : "The University of Oxford yesterday injected its new variant vaccine into people for the first time. Academics who created the original jab have updated their blueprint to target the variant first identified in South Africa, also known as B.1.351 or Beta. This Variant of Concern emerged last year and is still in the UK at low levels. It is also less susceptible to the vaccines than other strains, scientists believe. It became the prime candidate for the first “variant vaccine” and the AstraZeneca/Oxford team are now trialling the booster jab — called AZD2816 — in 2,250 volunteers from the UK, Poland, Brazil and South Africa. It was previously tested in a lab and on mice and the researchers said: "AZD2816 is immunogenic after a single dose and when used as a booster dose in animals primed with [the] original vaccine.”" . . . . https://www.telegraph.co.uk/news/2021/06/27/covid-booster-first-variant-vaccine-used-new-oxford-trial/

I heard Prof. Sir Andrew Pollard on R4 'Today' (1 hr 14 mins in) which prompted me to post. The Oxford Vaccine Group are looking to trial a tailored vaccine for a variant, in this case 'Beta' in the search to develop procedures for 'top up' vaccines as time goes on.

The choice of the 'Beta' variant for this seems odd but at the end of the short piece on R4, the question of 'delivery' is broached, patch and nasal spray being mentioned, and Prof. Pollard plays it down rather saying that formulating/testing of alternatives to the needle, will all take a bit longer and is one for 2022 !

Strikes me that he is not up to date with details of Scancell's 'Universal vaccine' and it's intended delivery methods in the coming trial.

The 'Covidity' project seems in more than one way, to be streets ahead of OVG as a 'top up' possibility - listening to Prof Pollard it seemed a bit passe to be looking at making booster vaccines for a single variant as it arises - by the time the vaccine is ready the variant will be well on it's way ?

Prof. Lindy ahead again ? Why so little acknowledgement of this ?

If not new, nice to see again. There's a pic in the link - can't quite see what's going on re. the dosing . . . .

""Scancell says preclinical data underlines potential of next-generation vaccine candidate as it prepares for phase I study

“Our next-generation COVID-19 vaccine has the potential to work alongside currently approved vaccines by protecting the population against new variants of SARS-CoV-2," said chief executive, Dr Cliff Holloway. Scancell Holdings PLC (LON:SCLP) said preclinical work has been published underlining the potential of its next-generation vaccine against variants of the COVID virus.

The news will provide a welcome boost to researchers planning phase I studies of SCOV1 and SCOV2, which were developed using the company’s ImmunoBody platform. The latest data showed the two vaccine candidates not only stimulated the T-cells in the immune system but also mobilised virus-neutralising antibodies that reacted with ’variants of concern’ such as the South African strain.

Scancell’s chief medical officer, Professor Lindy Durrant, described SCOV1 and SCOV2 as potentially providing an “extra layer of protective surveillance". In the same announcement, investors were told preparations were well underway for a two-stage clinical trial of the vaccine candidates taking place in South Africa and the UK

The COVIDITY study is a collaboration between Scancell, scientists in the newly established Centre for Research on Global Virus Infections and the Biodiscovery Institute at the University of Nottingham, and Nottingham Trent University. The programme, which has received funding from Innovate UK, will begin at the University of Cape Town Lung Institute and will involve unvaccinated, healthy adult volunteers.

It was not possible to carry out this very early work in the UK because of the rapid rollout of the vaccination programme, Scancell said. However, part two will take place in Britain. After a demonstration of safety, the company will seek approval from the Medicines & Healthcare Products Regulatory Agency to begin an extension of the study in which SCOV2 will be given to healthy volunteers who have already received two doses of an approved vaccine.

The immune responses from this UK part of the COVIDITY study will allow the scientists to assess the ability of SCOV2 to boost the immune response against current and potential future strains of COVID in those who have already been inoculated. “There is a significant threat from future mutations of the SARS-CoV-2 virus, as we have seen with the rapid transmission of the Delta variant,” said Scancell chief executive, Dr Cliff Holloway.

“Our next-generation COVID-19 vaccine has the potential to work alongside currently approved vaccines by protecting the population against new variants of SARS-CoV-2.”""

http://www.proactiveinvestors.co.uk/companies/news/952918/scancell-says-preclinical-data-underlines-potential-of-next-generation-vaccine-candidate-as-it-prepares-for-phas

. . . on the Scancell website now https://www.scancell.co.uk/a-novel-bivalent-dna-vaccine-encoding-both-spike-protein-receptor-binding-domain-and-nucleocapsid-protein-of-sars-cov-2-to-elicit-t-cell-and-neutralising-antibody-responses-that-cross-react-with-variants

Just to recap - "Of course all views are allowed and DE is free to do whatever he chooses but I come back to Crumbs 03.55 comment, "seems a bit of I'm (DE) taking my ball home" - I'd agree with that. It must be frustrating for David Evans to be unable to influence the BoD as before on matters that concern him - but to me he seems to have been a bit of a 'stickler' on this point of governance. Going backawhile, I thought his response to Vulpes selling into the rising SP was intemperate.

However DE's departure does feel a bit like losing an old Friend and as I posted to him earlier, "I would be very sad for you to miss out after all when the SP here suddenly hits the GBP8 as often predicted (wink)." DE claims he has better directions in which to place his money and I for one, would certainly like to see how that one turns out.

Anyway, good luck to him and to us too !"

Just to tidy up. Bermuda 14.11 - re. Konar's 12.32, I agreed with Konar's 1st 2 very clear paras. As for the 3rd para, (which had after all ended with 3 question marks) - my answer to your protest, specifically, would be no, same as yours in fact.

For me the 3rd para was a question, not a statement to endorse, BUT anyway, sorry to confuse.

Good post Konar. IMHO

I would have thought he had enough on his plate without this https://www.dailymail.co.uk/home/index.html

. . . . that we don't have a 'deanroberthunt' over here, (or a P7 or a Gecko for that matter). Sometimes it's really good to have big brother Admin watching over us !

Of course all views are allowed and DE is free to do whatever he chooses but I come back to Crumbs 03.55 comment, "seems a bit of I'm (DE) taking my ball home" - I'd agree with that. It must be frustrating for David Evans to be unable to influence the BoD as before on matters that concern him - but to me he seems to have been a bit of a 'stickler' on this point of governance. Going backawhile, I thought his response to Vulpes selling into the rising SP was intemperate.

However DE's departure does feel a bit like losing an old Friend and as I posted to him earlier, "I would be very sad for you to miss out after all when the SP here suddenly hits the GBP8 as often predicted (wink)." DE claims he has better directions in which to place his money and I for one, would certainly like to see how that one turns out.

Anyway, good luck to him and to us too !

"I will remind you all that SCOV2 is all about blood work "predicting protection against future variants". After demonstration of safety in Part 1 of the COVIDITY study in South Africa, Scancell will seek approval from the Medicines & Healthcare products Regulatory Agency (MHRA) to initiate a UK extension of the study in which SCOV2 will be given to healthy volunteers who have already received two doses of an approved vaccine. The immune responses from this UK part of the COVIDITY study will allow the Company to assess the ability of SCOV2 to boost the immune response against current and potential future strains of COVID-19 in pre-vaccinated individuals.

The SA arm is testing efficacy and i assume will be expanded into a major phase 3 trial with a placebo arm similar to what has already been observed. We will know we have it right as soon as Scancell opens the UK arm, the detected immune response in the SA arm will drive this.

The SA Arm allows direct comparison of the blood work against the UK arm of the trial in large numbers.

The odds are another variant may over take the Delta variant as time progresses which potentially could still infect UK vaccinated population even so the amount of infection in the vaccinated with Delta could still yield results in a major expansion of the UK arm v placebo

The UK arm opening is the Point that "economic expansion" Partners and Gov/Cepi intervention is most likely, i would suggest a lot of interest in Scancells published paper by the majors will prepare them for this moment because there are so few Universal Vaccines and certainly none that has the history of potency like Scancells Immunobody a fact that should not be dismissed lightly."

Thanks Inan

With the precision that's endemic to the Scancell world, I'd be surprised if a shell Company named Zakari which Bermuda tells us is the Greek word for 'sugar' is going to be used for anything other than Glycans . . . that makes sense to me.

Perhaps we'll get another subsidiary soon called, yes, 'Covidity' ?

Just my 2d. GLA

"Made of stronger stuff - T cells" - tell me about it. At the centre of Scancell's science.
Off topic but some might like it.

"Psychologist Kimberley Wilson and Dr Xand van Tulleken take a journey around the human body, asking what it can tell us about our innate capacity for change. In this episode, they zoom in on T cells: a type of white blood cell that forms a critical part of the body’s ability to fight off infection. Xand and Kimberley discover how scientists are hacking into the immune system and hear the story of 5-year-old Zac, who has undergone an innovative form of immunotherapy for leukemia."

On Radio 4 right now